标题
Centrally Acting Agents for Obesity: Past, Present, and Future
作者
关键词
-
出版物
DRUGS
Volume -, Issue -, Pages -
出版商
Springer Nature
发表日期
2018-07-16
DOI
10.1007/s40265-018-0946-y
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effects of 6-month treatment with the glucagon like peptide-1 analogue liraglutide on arterial stiffness, left ventricular myocardial deformation and oxidative stress in subjects with newly diagnosed type 2 diabetes
- (2018) Vaia Lambadiari et al. Cardiovascular Diabetology
- The therapeutic potential of targeting the peripheral endocannabinoid/CB 1 receptor system
- (2018) Joseph Tam et al. European Journal of Internal Medicine
- Effect of Lorcaserin Alone and in Combination with Phentermine on Food Cravings After 12-Week Treatment: A Randomized Substudy
- (2018) Candida J. Rebello et al. Obesity
- Progress and challenges in anti-obesity pharmacotherapy
- (2018) Daniel H Bessesen et al. Lancet Diabetes & Endocrinology
- Pharmacokinetic drug evaluation of extended release lorcaserin for the treatment of obesity
- (2017) Kathryn M Hurren et al. Expert Opinion on Drug Metabolism & Toxicology
- Early improvement in food cravings are associated with long-term weight loss success in a large clinical sample
- (2017) M Dalton et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes
- (2017) Melanie Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The atypical antipsychotic olanzapine causes weight gain by targeting serotonin receptor 2C
- (2017) Caleb C. Lord et al. JOURNAL OF CLINICAL INVESTIGATION
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Coadministration of lorcaserin and phentermine for weight management: A 12-week, randomized, pilot safety study
- (2017) Steven R. Smith et al. Obesity
- Comparison of Efficacy and Safety of Liraglutide 3.0 mg in Individuals with BMI above and below 35 kg/m²: A Post-hoc Analysis
- (2017) Carel le Roux et al. Obesity Facts
- Comparative efficacy of five long-term weight loss drugs: quantitative information for medication guidelines
- (2017) Z. Dong et al. Obesity Reviews
- Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder
- (2017) Julie R. Larsen et al. JAMA Psychiatry
- Peripheral cannabinoid-1 receptor blockade restores hypothalamic leptin signaling
- (2017) Joseph Tam et al. Molecular Metabolism
- Lorcaserin Administration Decreases Activation of Brain Centers in Response to Food Cues and These Emotion- and Salience-Related Changes Correlate With Weight Loss Effects: A 4-Week-Long Randomized, Placebo-Controlled, Double-Blind Clinical Trial
- (2016) Olivia M. Farr et al. DIABETES
- Efficacy and safety of liraglutide 3.0 mg for weight management are similar across races: subgroup analysis across the SCALE and phase II randomized trials
- (2016) J. Ard et al. DIABETES OBESITY & METABOLISM
- Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
- (2016) A Blackman et al. INTERNATIONAL JOURNAL OF OBESITY
- The relationship between early weight loss and weight loss at 1 year with naltrexone ER/bupropion ER combination therapy
- (2016) K Fujioka et al. INTERNATIONAL JOURNAL OF OBESITY
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist
- (2016) Peter Kühnen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early Weight Loss with Liraglutide 3.0 mg Predicts 1-Year Weight Loss and is Associated with Improvements in Clinical Markers
- (2016) Ken Fujioka et al. Obesity
- Effects of lorcaserin on pre-existing valvulopathy: A pooled analysis of phase 3 trials
- (2016) Neil J. Weissman et al. Obesity
- Evaluation of lorcaserin on progression of prediabetes to type 2 diabetes and reversion to euglycemia
- (2016) Richard Nesto et al. POSTGRADUATE MEDICINE
- Genetic variability in GLP-1 receptor is associated with inter-individual differences in weight lowering potential of liraglutide in obese women with PCOS: a pilot study
- (2015) Mojca Jensterle et al. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- GLP-1 Receptor Agonist Treatment Increases Bone Formation and Prevents Bone Loss in Weight-Reduced Obese Women
- (2015) Eva W. Iepsen et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in binge eating in non-diabetic obese individuals after 3 months of treatment with liraglutide – A pilot study
- (2015) Sarah Anne Robert et al. Obesity Research & Clinical Practice
- Health-related quality of life in two randomized controlled trials of phentermine/topiramate for obesity: What mediates improvement?
- (2015) Ronette L. Kolotkin et al. QUALITY OF LIFE RESEARCH
- Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release
- (2014) W. Timothy Garvey et al. DIABETES CARE
- Early weight loss while on lorcaserin, diet and exercise as a predictor of week 52 weight-loss outcomes
- (2014) Steven R. Smith et al. Obesity
- Cost-Effectiveness Analysis of Qsymia for Weight Loss
- (2014) Eric A. Finkelstein et al. PHARMACOECONOMICS
- Topiramate use in pregnancy and the birth prevalence of oral clefts
- (2014) Daniel Mines et al. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
- The insulin sensitizing effect of topiramate involves KATPchannel activation in the central nervous system
- (2013) C P Coomans et al. BRITISH JOURNAL OF PHARMACOLOGY
- Prevention of Type 2 Diabetes in Subjects With Prediabetes and Metabolic Syndrome Treated With Phentermine and Topiramate Extended Release
- (2013) W. Timothy Garvey et al. DIABETES CARE
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity
- (2013) S. R. Smith et al. DIABETES OBESITY & METABOLISM
- Tesofensine, a novel triple monoamine re-uptake inhibitor with anti-obesity effects: Dopamine transporter occupancy as measured by PET
- (2013) Lieuwe Appel et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS
- (2013) L van Bloemendaal et al. JOURNAL OF ENDOCRINOLOGY
- Anti-hypertensive treatment preserves appetite suppression while preventing cardiovascular adverse effects of tesofensine in rats
- (2013) Bo Hjorth Bentzen et al. Obesity
- Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults
- (2013) Louis J. Aronne et al. Obesity
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Tesofensine induces appetite suppression and weight loss with reversal of low forebrain dopamine levels in the diet-induced obese rat
- (2013) Henrik H. Hansen et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- Randomized Placebo-Controlled Clinical Trial of Lorcaserin for Weight Loss in Type 2 Diabetes Mellitus: The BLOOM-DM Study
- (2012) Patrick M. O'Neil et al. Obesity
- A Randomized, Double-Blind, Placebo-Controlled Study of an Oral, Extended-Release Formulation of Phentermine/Topiramate for the Treatment of Obstructive Sleep Apnea in Obese Adults
- (2012) David H. Winslow et al. SLEEP
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Short-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes
- (2011) Kana Inoue et al. Cardiovascular Diabetology
- Evaluation of the Abuse Potential of Lorcaserin, a Serotonin 2C (5-HT2C) Receptor Agonist, in Recreational Polydrug Users
- (2011) M J Shram et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- A One-Year Randomized Trial of Lorcaserin for Weight Loss in Obese and Overweight Adults: The BLOSSOM Trial
- (2011) Meredith C. Fidler et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- The Effect of Tesofensine on Appetite Sensations
- (2011) Jo-Anne Gilbert et al. Obesity
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Subjective and Objective Effects of the Novel Triple Reuptake Inhibitor Tesofensine in Recreational Stimulant Users
- (2010) K A Schoedel et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- The effect of the triple monoamine reuptake inhibitor tesofensine on energy metabolism and appetite in overweight and moderately obese men
- (2010) A Sjödin et al. INTERNATIONAL JOURNAL OF OBESITY
- Lorcaserin, A 5-HT2CReceptor Agonist, Reduces Body Weight by Decreasing Energy Intake without Influencing Energy Expenditure
- (2010) Corby K. Martin et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Tesofensine, a Novel Triple Monoamine Reuptake Inhibitor, Induces Appetite Suppression by Indirect Stimulation of α1 Adrenoceptor and Dopamine D1 Receptor Pathways in the Diet-Induced Obese Rat
- (2010) Anne Marie D Axel et al. NEUROPSYCHOPHARMACOLOGY
- Multicenter, Placebo-Controlled Trial of Lorcaserin for Weight Management
- (2010) Steven R. Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effect of Sibutramine on Cardiovascular Outcomes in Overweight and Obese Subjects
- (2010) W. Philip T. James et al. NEW ENGLAND JOURNAL OF MEDICINE
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics) – preclinical and clinical results
- (2009) Sten Madsbad BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM
- Serotonergic drugs and valvular heart disease
- (2009) Richard B Rothman et al. Expert Opinion On Drug Safety
- Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo
- (2009) Frank L. Greenway et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Effect of tesofensine on bodyweight loss, body composition, and quality of life in obese patients: a randomised, double-blind, placebo-controlled trial
- (2008) Arne Astrup et al. LANCET
- Weight Loss Produced by Tesofensine in Patients With Parkinson's or Alzheimer's Disease
- (2008) Arne Astrup et al. Obesity
- Rational Design of a Combination Medication for the Treatment of Obesity
- (2008) Frank L. Greenway et al. Obesity
- Lorcaserin (APD356), a Selective 5-HT2CAgonist, Reduces Body Weight in Obese Men and Women
- (2008) Steven R. Smith et al. Obesity
- Contribution of the active metabolite M1 to the pharmacological activity of tesofensinein vivo: a pharmacokinetic-pharmacodynamic modelling approach
- (2007) T Lehr et al. BRITISH JOURNAL OF PHARMACOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started